Description
Comprehensive PubChem-Based Research Overview
Molecular Identity & Structure
Semax is cataloged in PubChem under CID 9942963, with molecular formula C37H51N9O10 and molecular weight of ~765.9 g/mol [1]. It is classified as a synthetic derivative of adrenocorticotropic hormone (ACTH 4-10), modified for stability and activity in preclinical peptide research.
Neurochemical Research Applications
According to PubChem depositor data, Semax is studied in relation to neurotransmitter regulation and cognitive pathway signaling [1]. Laboratory experiments use it to investigate neurotrophin expression, GABAergic signaling, and dopaminergic/serotonergic modulation in controlled settings.
Epithelial Absorption & Delivery Studies
The nasal spray formulation provides a model for peptide stability, diffusion kinetics, and epithelial barrier penetration [2]. In vitro mucosal systems are often employed to compare nasal delivery with other peptide administration formats, supporting research on transport and absorption characteristics.
Synaptic Plasticity & Cognitive Models
Preclinical data aggregated in PubChem references link Semax to studies of learning, memory, and neuroprotection [1][2]. While these remain strictly non-clinical, the peptide is widely used in mechanistic neuroscience research, where nasal spray delivery enables reproducible administration across test models.
Analytical & Experimental Utility
Semax’s PubChem identifiers and sequence data support assay reproducibility, SAR studies, and analytical QC in peptide labs. Researchers integrate the nasal spray format into screening platforms that assess stability, receptor engagement, and downstream transcriptional effects.
There are no reviews yet.